Neuropharmacology of alcohol addiction
- PMID: 18311194
- PMCID: PMC2442440
- DOI: 10.1038/bjp.2008.30
Neuropharmacology of alcohol addiction
Abstract
Despite the generally held view that alcohol is an unspecific pharmacological agent, recent molecular pharmacology studies demonstrated that alcohol has only a few known primary targets. These are the NMDA, GABA(A), glycine, 5-hydroxytryptamine 3 (serotonin) and nicotinic ACh receptors as well as L-type Ca(2+) channels and G-protein-activated inwardly rectifying K(+) channels. Following this first hit of alcohol on specific targets in the brain, a second wave of indirect effects on a variety of neurotransmitter/neuropeptide systems is initiated that leads subsequently to the typical acute behavioural effects of alcohol, ranging from disinhibition to sedation and even hypnosis, with increasing concentrations of alcohol. Besides these acute pharmacodynamic aspects of alcohol, we discuss the neurochemical substrates that are involved in the initiation and maintenance phase of an alcohol drinking behaviour. Finally, addictive behaviour towards alcohol as measured by alcohol-seeking and relapse behaviour is reviewed in the context of specific neurotransmitter/neuropeptide systems and their signalling pathways. The activity of the mesolimbic dopaminergic system plays a crucial role during the initiation phase of alcohol consumption. Following long-term, chronic alcohol consumption virtually all brain neurotransmission seems to be affected, making it difficult to define which of the systems contributes the most to the transition from controlled to compulsive alcohol use. However, compulsive alcohol drinking is characterized by a decrease in the function of the reward neurocircuitry and a recruitment of antireward/stress mechanisms comes into place, with a hypertrophic corticotropin-releasing factor system and a hyperfunctional glutamatergic system being the most important ones.
Comment in
-
Neuropharmacology of addiction--setting the scene.Br J Pharmacol. 2008 May;154(2):259-60. doi: 10.1038/bjp.2008.131. Epub 2008 Apr 14. Br J Pharmacol. 2008. PMID: 18414384 Free PMC article.
References
-
- Addolorato G, Abenavoli L, Leggio L, DeLorenzi G, Ferrulli A, Caputo F, et al. Baclofen: clinical data Drugs for Relapse Prevention of Alcoholism 2005aBirkhäuser: Basel; 171–180.In: Spanagel R, Mann K (eds)
-
- Addolorato G, Caputo F, Capristo E, Domenicali M, Bernardi M, Janiri L, et al. Baclofen efficacy in reducing alcohol craving and intake: a preliminary double-blind randomized controlled study. Alcohol Alcohol. 2002;37:504–508. - PubMed
-
- Addolorato G, Leggio L, Abenavoli L, Gasbarrini G. On behalf of the Alcoholism Treatment Study Group neurobiochemical and clinical aspects of craving in alcohol addiction: a review. Addict Behav. 2005b;30:1209–1224. - PubMed
-
- Allgaier C. Ethanol sensitivity of NMDA receptors. Neurochem Int. 2002;41:377–382. - PubMed
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical
Miscellaneous